RxDoctor Payments Data

Daniel Learned, MD

Retina Specialist · Santa Barbara, CANPI 1033406780

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Regeneron at 34.8% of the total.

$48,628in general payments, 2019–2025

Across 152 payments — averaging $319.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$17K
  • Alimera Sciences, Inc.$8K
  • Genentech, Inc.$7K
  • Genentech USA, Inc.$6K
  • Alcon$6K
  • Carl Zeiss Meditec, Inc.$2K
  • plus $2K from 8 others
$97,829in research payments, 2019–2025

Across 30 payments — averaging $3260.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$98K

What the payments were for

  • Consulting fees$25,77053%
  • Speaking & faculty fees$12,20025%
  • Travel & lodging$3,6878%
  • Food & beverage$4,84110%
  • Gifts$2,1294%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,628 in reported general payments places this provider in the 85th percentile of 187 retina specialist providers in California.

See all retina specialist providers in California

Medicare billing

Part B allowed, 2024
$7,317,862
Medicare patients
1,964
Services billed
57,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate194$8,242
LumiganBimatoprost12$5,930
CombiganBrimonidine Tartrate/Timolol11$4,903
Atropine Sulfate83$3,403
Bromfenac Sodium18$2,917
Brimonidine Tartrate76$2,863
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat129$2,147
Ketorolac Tromethamine93$2,109
Latanoprost204$1,707
ErythromycinErythromycin Base125$1,099
Ciprofloxacin Hcl60$791
Ofloxacin19$164
Timolol Maleate27$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$423$10,83423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 187 retina specialist providers in California.

Other retina specialist in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →